BS_T1DVKKJB
Supratentorial Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Supratentorial Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Supratentorial Ependymoma
- overall_survival_months
- 140.76872536136662
- age_years
- 8.611
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.467
- HYPOXIA+0.389
- ANGIOGENESIS+0.332
- INFLAMMATORY_RESPONSE+0.323
- WNT_BETA_CATENIN_SIGNALING+0.295
- UV_RESPONSE_UP+0.289
- PANCREAS_BETA_CELLS+0.257
- INTERFERON_GAMMA_RESPONSE+0.254
- INTERFERON_ALPHA_RESPONSE+0.244
- GLYCOLYSIS+0.213
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.318
- PROTEIN_SECRETION-0.316
- MYC_TARGETS_V1-0.288
- MITOTIC_SPINDLE-0.213
- MYC_TARGETS_V2-0.177
- ANDROGEN_RESPONSE-0.148
- TGF_BETA_SIGNALING-0.106
- PEROXISOME-0.095
- FATTY_ACID_METABOLISM-0.094
- HEME_METABOLISM-0.093
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_T1DVKKJB | EPN | Supratentorial EPN | 0.933 |
| 2 | SJEPD034_D.RNA-Seq | EPN | Supratentorial EPN | 0.808 |
| 3 | BS_PJPGVD62 | Ependymoma NOS | — | 0.802 |
| 4 | X41226e40.d143.43b1.ac92.023809990077 | — | cohortA1 | 0.791 |
| 5 | SRR2778056 | — | — | 0.788 |
| 6 | BS_0QYS36NR | Ependymoma NOS | — | 0.783 |
| 7 | R107 | — | — | 0.780 |
| 8 | BS_RXN5T5YT | Diffuse intrinsic pontine glioma | — | 0.779 |
| 9 | BS_N4B1SZZH | Med | Medulloblastoma | 0.772 |
| 10 | BS_6H1C1ME9 | Posterior Fossa Ependymoma | — | 0.771 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.467 | Inavolisib | — uncovered |
| HYPOXIA | 0.389 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.332 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.323 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.295 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.289 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.257 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.254 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.244 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.213 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.204 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| APOPTOSIS | 0.169 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.159 | Idelalisib | — uncovered |
| COAGULATION | 0.137 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.125 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.125 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.111 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.111 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.108 | Inavolisib | — uncovered |